← Back

Wire · opportunities

FDA approves Novartis' Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

Novartis secured FDA approval for Cosentyx as the first anti-IL-17 biologic treatment for polymyalgia rheumatica in adults with inadequate response or intolerance to corticosteroids, based on positive Phase III trial results. This offers an alternative to long-term steroid use, which carries significant health risks and relapse rates.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Your drug development just hit a new bar in PMR treatment that reduces steroid reliance. If you target autoimmune diseases, this FDA nod changes competitive standards and clinical expectations right now.

◆ Coverage

3 sources · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalautoimmune-diseasebiologic-therapypolymyalgia-rheumaticaFDA-approval